Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-15 in sleep disorders of children with ASD
NCT02757066Phase 3Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jun 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of melatonin in sleep disorder (3 arms), sponsored by Nobelpharma Co., Ltd. Primary endpoint: Sleep latency with electronic sleep diary at 2 weeks. Started Jun 2016; status: completed.
02
Drugs
melatonin
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NCT02757066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757066.